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BACKGROUND: Capillary hemangiomas, the most common tumors in young children, consist of
proliferating capillary vessels and endothelial cells. These tumors also contain large numbers of
mast cells, compared with the normal surrounding skin or tissue. We have recently shown that
stem cell factor (SCF), the gene product of the murine steel locus, can act as a chemoattractant for
mast cells. In this study, we investigated whether SCF might be involved in the recruitment and
maintenance of mast cells in hemangiomas.
EXPERIMENTAL DESIGN: Cultured endothelial cells derived from a murine hemangioma were
compared with normal vascular endothelial cells for the ability to produce and release SCF, a
mitogen for mast cells.
RESULTS: Conditioned medium from hemangioma-derived endothelial cells stimulated the proliferation of cultured mast cells. This proliferative activity was potentiated by interIeukin-3. The
same conditioned medium was unable to stimulate proliferation of mast cells expressing a defective
receptor for SCF. The medium was also unable to stimulate proliferation when it was preincubated
with neutralizing antibodies specific for SCF. Immunoprecipitation and Western blot analysis of
the conditioned media from hemangioma cells and normal endothelial cells demonstrated the
31,000 molecular weight SCF in hemangioma-conditioned medium only. In addition, proliferative
activity for mast cells could not be demonstrated in the conditioned medium of the normal
endothelial cells, although Northern blot analysis indicated that both normal and hemangiomaderived endothelial cells express SCF mRNA. Reverse transcriptase-polymerase chain reaction
techniques were used to amplify the DNA sequence coding for the proteolytic cleavage site used
for release of SCF. Results indicated that both normal and hemangioma-derived endothelial cells
express the same transcript for SCF.
CONCLUSIONS: Our data suggest that increased release of SCF is a property of hemangiomaderived endothelial cells that may account for the high numbers of mast cells observed in hemangioma tissue. This increased release of SCF is not due to alternate splicing of SCF transcripts by
hemangioma cells.
Additional key words: Mast cells, Steel factor, kit ligand, Mast cell growth factor, Angiogenesis.
Hemangiomas, the most common tumors of infancy,
vary from small, innocuous marks to mutilating, and in
some cases life-threatening, lesions. Small hemangiomas
may impinge on vital structures, such as the cornea or
upper airways, whereas hemangiomas that grow to a large
size may actually distort adjacent structures and cause
functional impairment. Congestive heart failure often
occurs with hepatic hemangiomatosis (1), and acute respiratory distress is a complication of subglottic hemangiomas (2). Gastrointestinal bleeding and obstruction
can occur as well as perforation of the small intestine
(3). A life-threatening thrombocytopenia with widespread hemorrhage (Kasabach-Merritt syndrome) may
occur in association with a single enlarging hemangioma
or diffuse hemangiomatosis (4),

Hemangiomas consist of an irregular proliferation of
capillary vessels and/or endothelial cells. They characteristically exhibit a period of rapid proliferation followed
by slow spontaneous involution and disappearance. Interesting to note, the presence of mast cells correlates
with the growth of this tumor. The density of mast cells
in rapidly growing hemangiomas is at least five times
that of normal skin, and the density returns to normal
at the time of tumor regression (5, 6). The signal(s)
responsible for these changes in mast cell density have
not been explored.
Mast cells can exhibit directed motility (i.e., chemotaxis). Mast cells migrate in response to tumor implantation (7), tumor-derived peptides (8), matrix components, such as laminin (9), and interleukin-3 (IL-3) (10).
166
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e have also found that mast cells migrate in response
to stem cell factor, a hematopoietic growth factor (11).
Stem cell factor (SCF) (12), also known as mast cell
growth factor (MCGF) (13) or kit ligand (14), is a potent
stimulator of mast cell proliferation and can potentiate
IL-3-induced proliferation. Using cells derived from a
murine hemangioendothelioma (15), we investigated
whether altered production or release of SCF might be a
property of hemangiomas by comparing the amount of
SCF produced and released by hemangioma-derived
endothelial cells relative to normal endothelial cells.
EXPERIMENTAL DESIGN
Cultures of endothelial cells derived from murine hemangiomas, murine aorta, and murine lung and brain
microvessels were established. Growth media conditioned by these cells were tested for the ability to stimulate bone marrow-derived mast cell proliferation, a
characteristic of SCF. Confirmation of SCF identity was
achieved by antibody neutralization of mitogenic activity
as well as by immunoprecipitation followed by Western
blot analysis. Northern analysis was used to indicate steady
state levels of mRNA for SCF. Reverse transcriptasepolymerase chain reaction techniques were used to determine if the release of SCF was a function of alternative
splicing of mRNA transcripts produced in these cells.
RESULTS AND DISCUSSION
To determine whether hemangioma cells produce and
release a factor(s) that stimulate(s) the proliferation of
mast cells, we tested the ability of medium conditioned
by cells of a spontaneous hemangioma (EOMA cells) to
stimulate the proliferation of cultured mast cells (Fig.
LA). Undiluted conditioned medium produced a two to
three-fold increase in mast cell proliferation relative to
unstimulated controls. Dilution of the conditioned medium reduced the proliferative response, indicating that
the response was dose-dependent. The response to undiluted conditioned medium was equivalent to the response of the mast cells to 10 ng/ml recombinant rat
SCF (rrSCF). The proliferative response to conditioned
medium was potentiated by the presence of 10 U/ml IL-3,
as has been shown previously for purified SCF (12).

167

W 42 mast cells possess a defective c-kit receptor tyrosine kinase and do not grow or migrate in response to
SCF. As shown in Figure IB, these cells failed to proliferate in the presence of EOMA-conditioned medium,
suggesting that the proliferative activity is mediated via
activity of the c-kit receptor. The result was not due to
a general loss of proliferative potential in these cells;
they demonstrated a normal proliferative response to
IL-3.
To verify that the proliferative activity in the conditioned medium from the EOMA cells was due to the
presence of SCF, the conditioned medium was preincubated with antibody capable of neutralizing the activity
of rrSCF. One hour of incubation with antibody was
sufficient to completely abolish the proliferative activity
in the conditioned medium or in control medium containing 50 ng/ml rrSCF (Fig, 2). These results suggest
that all of the mast cell stimulatory activity present in
hemangioma cell-conditioned medium can be attributed
to SCF.
To determine whether normal endothelial cells also
release SCF, conditioned media from the hemangiomaderived (EOMA) and aortic (MAEC) endothelial cells
were compared. Significant proliferative activity for
cultured mast cells was noted only in the EOMAconditioned medium (Fig. 3). The proliferative response
of the mast cells to EOMA-conditioned medium supplemented with 10 U/ml of IL-3 was significantly higher
than the proliferative response to 10 U/ml of IL-3 alone,
indicating that the proliferative response was not due
merely to the presence of IL-3. No statistically significant proliferative activity was noted in the conditioned
medium from MAEC when tested alone or when supplemented with IL-3.
Murine stem cell factor (kit Iigand-1 [KL-1]) is synthesized as a 45 kD (248 amino acid)-membrane protein
(13,14, 16,17). The membrane-bound form is processed
by a serine protease at the cell surface (18). Proteolytic
cleavage releases a soluble, biologically active form of
stem cell factor with a molecular weight of approximately
31 kD. This soluble protein is analogous to the isolated
natural rat protein that has been completely sequenced
and that contains 164 or 165 amino acids (19). Both rat

DMEML
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FlG. 1. A Dose-dependent stimulation of mast cell proliferation by EOMA
conditioned medium. Cultured bone
marrow-derived mast cells were incubated with basal medium alone, basal
medium containing 10 ng/ml rrSCF, or
conditioned medium (CM.) from the hemangioendothelioma cells with (+) or
without (-) 10 U/ml IL-3. Cell numbers
were determined after 72 hours of incubation. Data represent means ± SEM. B
Failure of mutant mast cells to respond
to EOMA conditioned medium. W42
mast cells were incubated with basal medium, with basal medium containing
high levels of IL-3, with basal medium
containing 100 ng/ml rrSCF and in various concentrations of EOMA conditioned medium. Cell numbers were determined after 72 hours of incubation.
Data represent means ± SEM.
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heavy chains of the rabbit immunoglobulin that were
dissociated from the Protein-A Sepharose (as visualized
in Fig. 4, lane 1, containing fresh, nonconditioned
medium subjected to immunoprecipitation). A second
band appearing at approximately 45 kD in the EOMAconditioned medium has not been conclusively identified
but may represent full-length SCF.
Northern blot hybridization using a 32 P-labeled cDNA
probe specific for murine SCF revealed a single band of
radioactivity at approximately 7.5 kb (Fig. 5). This
mRNA for SCF was present in both the MAEC and
EOMA cells. This suggests that both endothelial cell
types have the ability to make SCF mRNA and, presumably, SCF protein. Human umbilical vein endothelial
cells have recently been shown to express SCF mRNA,
although the existence of the protein in these cells was
not demonstrated (21).

FIG. 2. Effect of anti-SCF antibodies on the mast cell proliferative
activity in EOMA conditioned medium. Cultured bone marrow-derived
mast cells were incubated with basal medium alone, or in basal medium
containing 50 ng/ml rrSCF and EOMA conditioned medium preincubated with (+) or without {—) polyclonal antibodies against rat SCF.
Cell numbers were determined after 72 hours of incubation. Data
represent means ± SEM.

NEQ.CTHL
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FIG. 3. Comparison of the mast cell proliferative activity in EOMA
conditioned medium and medium conditioned by normal endothelial
cells. Cultured bone marrow-derived mast cells were incubated with
basal medium alone, basal medium containing 10 U/ml IL-3, or undiluted conditioned medium from EOMA or MAEC with or without 10
U/ml IL-3. Cell numbers were determined after 72 hours of incubation.
Data represent means ± SEM.
and human SCF migrate over a range of molecular weight
of 28,000 to 35,000 on sodium dodecyl sulfate (SDS)
polyacrylamide gels because of extensive and heterogeneous glycosylation of the protein (19, 20).
A protein with a molecular weight of approximately
31,000 was precipitated from the conditioned medium of
the EOMA cells (Fig. 4, lane 3). This same protein could
not be precipitated from the conditioned medium of the
MAEC (Fig. 4, lane 2), even though it was prepared from
three times the number of cells used to generate conditioned medium from the EOMA cells. The major bands
at approximately 25 and 50 kD represent the light and
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FlG. 4. Demonstration of stem cell factor in conditioned media of
EOMA and normal endothelial cells. Conditioned media from EOMA
and MAEC as well as fresh, nonconditioned medium were immunoprecipitated with rabbit anti-murine SCF and Protein-A Sepharose, separated by SDS polyacrylamide gel electrophoresis, blotted to nitrocellulose, and probed with the same polyclonal antibody specific for SCF.
Immunodetected proteins were visualized using a chemiluminescence
detection system. Soluble SCF (molecular weight =s 31,000) is indicated
by the arrow. Molecular weight standards (in kilodaltons) are also
indicated at the left. Lane 1, fresh medium; lane 2, MAEC-conditioned
medium; lane 3, EOMA-conditioned medium.
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KL-2; an alternatively spliced version of KL-1, lacks
exon 6, which codes for the cleavage site found in KL-1.
An alternative but much less efficient cleavage site exists
o
in KL-2. As a consequence, the protein encoded by KL-2
tends to remain cell-associated. Flanagan et al. (26)
reported that the ratio of KL-1 to KL-2 mRNAs varied
in different tissues, indicating that the alternative splicing
event that creates them is regulated in a tissue-specific
manner. They suggested that regulated alternative splic9.5->
ing may provide a mechanism for the differential expression of the cell surface or soluble forms of SCF in different
7.5-»
cells. To determine whether differential release of soluble
SCF by hemangioma-derived and normal endothelial cells
was due to alternative splicing, reverse transcriptase4.4-»
polymerase chain reaction (RT-PCR) techniques were
used to identify the transcripts in these cells. Primers
were designed to amplify a portion of the DNA sequence
that included exon 6. The amplified segment of DNA was
predicted to be 185 base pairs in length if exon 6 was
2.4->
present, and 101 base pairs in length if exon 6 was absent.
Figure 6 illustrates the PCR products obtained by
amplification of cDNA from BALB/c-3T3 fibroblasts
(lane 1) as well as several hemangioma-derived endothe1.4-»
lial cells (lanes 2-4) and normal endothelial cells (lanes
kb
5 and 6). BALB/c-3T3 fibroblasts are known to express
relatively large amounts of KL-1 (26) and were included
as a positive control. Sl/Sl d fibroblasts have a deletion
in the SCF gene that removes the transmembrane and
FIG. 5. Northern blot analysis of mRNA from EOMA and MAEC. intracellular domains (26). These cells only produce a
Three micrograms of mRNA from EOMA and MAEC were separated secreted form of SCF, which lacks a portion of the
on an agarose-formaldehyde
gel, transferred to nylon membranes, sequence amplified by our primers. Therefore, cDNA
hybridized with a a2P-labeled cDNA probe specific for murineSCF, and from these cells was included as a negative control*(farce
processed for autoradiography.
7). A 185-base pair DNA fragment was amplified in 3T3
cells and represents the KL-1 transcript. No 101-base
Several growth factors are synthesized as transmem- pair fragment was amplified, indicating the absence of
brane precursors that are proteolytically processed to the the KL-2 transcript. This finding supports the
generate soluble factors that function in juxtacrine and/ Northern analysis data that demonstrated only a single
or paracrine stimulation. Colony stimulating factor-1 SCF mRNA (Fig. 5). Sl/Sl d fibroblasts did not exhibit
(CSF-1), which is genetically and structurally related to either PCR product as expected. The larger molecular
SCF (22), has been shown to be cleaved proteolytically weight bands in farce 8 represent genomic DNA evident
to produce a soluble growth factor (23, 24). Other mem- in control tubes containing no reverse transcriptase (i.e.,
brane growth factors include tumor necrosis factor a samples in which cDNA could not be synthesized from
(TNFa) (25) as well as transforming growth factor a the RNA [data not shown]). The same 185-base pair
(TGFa) and several other members of the epidermal fragment amplified in the 3T3 fibroblasts was amplified
growth factor family (18).
in three different hemangioma-derived endothelial cell
Little work has been done to examine the regulation lines: the spontaneous EOMA cells (lane 2) as well as
of SCF expression and processing. Huang et al. (17) the retrovirus-induced Py4-1 (lane 3) and bEnd cells
demonstrated that proteolytic cleavage of the membrane- (lane 4). These data suggest that the production of SCF
bound SCF in COS-1 transfected cells was stimulated by is a general property of hemangiomas and not just a
the protein kinase C inducer phorbol 12-myristate 13- property of the EOMA cells. In addition, the same tranacetate and the calcium ionophore A23187, suggesting script was identified in aortic (lane 5), lung (lane 6), and
differential regulation of this process. The data presented brain (data not shown) endothelial cells, indicating that
here indicate an inherent difference between the endo- this is a general property of endothelial cells, both large
thelial cells of the hemangioma and those found in the vessel and microvascular in origin. Finally, RT-PCR
normal vasculature. The data suggest that hemangioma- techniques were also used with human microvascular
derived endothelial cells are able to release soluble SCF endothelial cells and primers specific for the human SCF
whereas normal endothelial cells are not. Both cell types sequence. The larger KL-1 sequence was amplified in
make SCF and transport it to the cell surface, but only these cells as well (data not shown), indicating that
the hemangioma-derived cells appear to be able to release production of SCF is not just a property of murine
significant quantities of the soluble protein.
endothelial cells. However, a small amount of the KL-2
Huang et al. (17) showed that the soluble form of SCF cDNA was also amplified in the human cells, which was
is generated by efficient proteolytic cleavage from a not evident in the murine endothelial cells.
transmembrane precursor termed kit Iigand-1 or KL-1.
U
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minogen activator and decreased production of plasminogen activator inhibitors. If this excess proteolytic activity was neutralized by adding exogenous serine protease
inhibitors, normal capillary-like tubules were formed by
the cells. These findings suggest that the difference between hemangioma-forming endothelial cells and normal
endothelial cells lies in their protease production. Increased protease production would provide the means for
release of SCF by the hemangioma-derived endothelial
cells that was diminished or absent in normal endothelial
cells. Western blotting techniques were used to demonstrate the presence of SCF in all endothelial cells tested
in this study, whereas immunoprecipitation followed by
Western blotting confirmed the release of SCF into the
medium of the three different hemangioma-derived endothelial cells and confirmed the absence of release into
the medium of normal brain microvascular endothelial
cells (data not shown).
Hemangiomas are benign tumors made up of proliferating endothelial cells and capillaries and are found in
children. Mast cells are observed in large numbers in
these proliferating hemangiomas both in humans and in
mice injected with EOMA cells (personal communication, Dr. Michael O'Reilly, Children's Hospital, Harvard
Medical School, Boston). The presence of mast cells in
hemangiomas has never been completely understood.
The data presented in this study indicate that endothelial
cells in the hemangioma release soluble SCF, which may
act to recruit mast cells into the hemangioma (11). Once
inside the tumor mass, the mast cells may also proliferate
and degranulate in response to SCF (13, 30). DegranuFIG. 6. Polymerase chain reaction (PCR) amplification of SCF lation with subsequent release of mast cell products, such
cDNAs from hemangioma-derived and normal endothelial cells. PCR as heparin, histamine, or tumor necrosis factor a may
was performed on first strand cDNA prepared using reverse transcrip- then stimulate the growth of the endothelial cells of the
tase and total RNA from (a) BALB/c-3T3 fibroblasts, (b) EOMA cells,
(c) Py4-1 cells, (d) bEnd cells, (e) murine aortic endothelial cells, (f) hemangioma (5). Thus, a two-way interaction between
murine lung microvascular endothelial cells, and (g) Sl/Sld fibroblasts. endothelial and mast cell products may account for the
The PCR products were separated on an 8% polyacrylamide gel under rapid growth seen with this tumor.
nondenaturing conditions. DNA bands were demonstrated by silver
staining. A DNA ladder, included in lane 8, indicates the migration of
METHODS
DNA fragments in 100-base pair increments (100, 200, 300 base pairs,
etc.)
1

2

3

4

5

6

7

8

REAGENTS

Angiogenesis is the process by which new capillaries
are formed from preexisting blood vessels. Endothelial
cells respond to angiogenic stimuli by producing proteases to degrade their investing basement membrane
and surrounding matrix. The endothelial cells then migrate into the interstitium and proliferate to form
sprouts. The anastomosis of two sprouts generates new
capillary loops through which blood may flow. Expression of the polyoma virus middle T (mT) oncogene
severely perturbs the ability of endothelial cells to form
normal vascular structures. Infection of mice with a
retrovirus carrying the m T oncogene results in the rapid
formation of cavernous hemangiomas (27). These hemangiomas provide a source of stable endothelioma
(End) cell lines that retain specific endothelial cell markers and express mT antigen. Injection of these cells into
mice results in the rapid formation of hemangiomas,
which demonstrates that these cells are the primary
cause of the lesions (28). Montesano et al. (29) demonstrated that the brain End (bEnd) hemangioma cells
exhibited increased production of urokinase-type plas-

Recombinant rat stem cell factor (rrSCF) and neutralizing
antibodies for rrSCF were generously provided by Dr. Krisztina
Zsebo, Amgen Inc., Thousand Oaks, CA. Polyclonal rabbit antimurine stem cell factor as well as recombinant murine interleukin-3 (IL-3) were obtained from Genzyme (Cambridge, MA).
One unit of IL-3 is defined as the amount required to support
half-maximal tritiated thymidine incorporation by 2.5 X 103
FDC-P2 cells in 100-/U cultures as described by Prestidge et al.
(31).
CELLS

The spontaneous hemangioma, or EOMA, cells were the
kind gift of Dr. Robert Auerbach, University of Wisconsin,
Madison, WI. These endothelial cells (15) were originally derived by Hoak et al. (32) from a mixed hemangioendothelioma
arising spontaneously in a mouse. Py4-1 cells were generously
provided by Dr. Victoria Bautch, University of North Carolina,
Chapel Hill, NC. These endothelial cells were isolated from
hemangiomas induced by expression of the polyoma early region gene in transgenic mice (33). They exhibit properties of
differentiated endothelial cells but are tumorigenic when reintroduced into mice. Endothelioma cells isolated from primary
murine brain endothelial cells (bEnd) infected with a middle T
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linked to Protein A-Sepharose (Pharmacia, Piscataway, NJ)
and centrifuged. The samples were then immunoprecipitated
overnight at 4" C using polyclonal rabbit anti-murine stem cell
factor (Genzyme, Cambridge, MA) at a concentration of 2 ngj
ml previously bound to Protein-A Sepharose. The Sepharose
with bound SCF was collected by centrifugation, rinsed well
with Tris-buffered saline (TBS, 10 mM Tris-HCl, pH 7.5, 0.15
M NaCl) and boiled in SDS sample buffer lacking 2-ME to
release the SCF. After boiling, 2-ME was added to the samples,
which were loaded on a 9.5 to 16% SDS polyacrylamide gradient
gel and run under standard denaturing conditions (Laemmli).
Separated proteins were blotted to nitrocellulose using 25 mM
Tris, pH 8.3, 192 mM glycine, 20% methanol, and 0.02% SDS
in a wet transblot system (BioRad, Hercules, CA). The nitrocellulose was blocked with 3% gelatin in TBS and incubated
with rabbit anti-murine SCF at a concentration of 5 Mg/ml in
Cultured bone marrow-derived mast cells (CMC) were iso- TBS with 0.1% Tween 20 (TTBS) and 1% gelatin for 2 hours
lated from marrow washed from femurs of WBB6 mice. at room temperature or overnight at 4° C. The nitrocellulose
Briefly, femurs were dissected free of muscle and connective was washed six times (5 minutes each wash) in TTBS, incutissue, and the marrow cavity was rinsed two times with 1 ml bated with horseradish peroxidase-conjugated goat anti-rabbit
of sterile Minimal Essential Medium a (MEMa, GIBCO Lab- IgG (Kirkegaard & Perry Laboratories, Gaithersburg, MD),
oratories, Grand Island, NY). The cells were pooled, centrifuged and diluted 1:20,000 in TTBS with 1% gelatin for 1 hour at
(200 g for 10 minutes), and resuspended at a concentration of room temperature. The nitrocellulose was again washed six
1 to 5 X 10s cells/ml in MEMa containing 10% FBS, 10% times in TTBS, drained briefly, and incubated in Enhanced
pokeweed mitogen-stimulated spleen cell conditioned medium Chemiluminescence (ECL, Amersham, Arlington Heights, IL)
as a source of IL-3 (35), 7 X 10"6 M 2-mercaptoethanol (2-ME), substrate reagent for 1 minute. The blot was wrapped in Saran
2 mM L-glutamine, 100 IU/ml penicillin, and 100 ng/m\ strep- Wrap™ and exposed to film (ECL Hyperfilm, Amersham,
tomycin. One half of the medium was replaced with fresh Arlington Heights, IL) for 1 to 2 minutes. The molecular
medium every 7 days. Only mast cells remain in culture after weights of the immunodetected bands from conditioned media
30 days, as determined by positive staining with alcian blue.
were compared to molecular weight standards.
Homozygous mutant W42/W42 mast cells were the generous
gift of Dr. Alan Bernstein. These cells express a c-kit receptor
RNA Isolation. Poly A+ RNA (mRNA) was isolated from 1
that is deficient in tyrosine kinase activity. They were main- to 2 X 10' cells using the Poly ATtractR System (Promega
tained in the same culture medium as the CMC and were Corp., Madison, WI). Briefly, cells were extracted in guanidine
passaged every 3 to 4 days to keep the cell density at approxi- thiocyanate/SDS extraction buffer containing 2% 2-ME and
mately 5 X 105 cells/ml.
sonicated for 15 to 30 seconds. Biotinylated oligo (dT) probe
(2.5 fil of a 50-pmole//xl solution) was added to the RNA, mixed
CONDITIONED MEDIUM
well, and incubated at 70° C for five minutes. The lysate was
Conditioned medium used to stimulate mast cell proliferation transferred to a sterile 15-ml Corex tube and centrifuged at
was prepared by incubating cultures of EOMA or MAEC in 12,000 X g for 10 minutes at room temperature to clear the
serum-free MEMa for 24 hours. These conditioned media were homogenate of cell debris and precipitated proteins. The sucollected, filtered, supplemented with FBS (to a final concen- pernatant was removed, added to a tube containing a suspentration of 10%) and 2-ME (to 7 X 106 M) and added to target sion of streptavidin paramagenetic particles (in 0.5 mis of 0.5x
mast cells for proliferation assays as described below. For (sodium chloride/sodium citrate) and mixed well. The magimmunoprecipitation and Western analysis, the cells were netic particles with bound mRNA were immobilized with a
grown in DMEM and supplemented as described above for magnet, and the supernatant was removed. The particles were
culture. The media were collected, filtered, and immunoprecip- washed four times with 0.1X SSC (1.5 ml per wash). After the
final wash, the supernatant was removed, and the mRNA was
itated with a polyclonal rabbit anti-murine SCF (see below).
eluted by suspending the magnetic particles in 1 ml of RNasefree water. The particles were immobilized with a magnet, and
PROLIFERATION ASSAYS
the aqueous phase containing the mRNA was transferred to a
Four to 5000 CMC or W42 mutant mast cells were resus- sterile RNase-free tube. The RNA was concentrated by adding
pended in fresh or conditioned medium (both containing 10% 0.1 volume of 3 M sodium acetate (pH 5.2) and 2.5 volumes of
FBS and 7 X 10-6 M 2-ME [basal medium]) and plated in 96- ethanol and by incubating overnight at -70" C. The RNA was
well tissue culture trays. In some experiments, the conditioned pelleted by centrifugation at 12,000 x g for 10 minutes at 4° C
medium was also supplemented with murine IL-3. The mast and resuspended in RNase-free deionized water at 1 to 2 fig/fil.
cells were incubated for 72 hours at 37" C and counted in a
Northern Hybridization. RNA samples were separated in
hemacytometer.
0.8% agarose-formaldehyde gels using 40 mM MOPS (pH 7.0)/
In the experiments involving neutralizing antibodies, condi- 10 mM sodium acetate/1 mM EDTA as the running buffer and
tioned medium and medium containing rrSCF were incubated running at 5 volts/cm for 4 hours. Three micrograms of mRNA"
with polyclonal rabbit anti-rrSCF antibodies (Amgen, Inc.) for were denatured in 2.2 M formaldehyde/50% of formamide
1 hour at 37" C before mast cells were added. The mast cells (v/v) and loaded per lane. RNA molecular weight markers
were incubated an additional 72 hours and counted as described were also included on the gel. The separated nucleic acids
above.
were transferred overnight to HybondR nylon membranes
(Amersham, Arlington Heights, IL) by wicking with northern
IMMUNOPRECIPITATION AND WESTERN BLOT ANALYSIS
transfer solution reagent (Biotecx, Houston, TX). After transConditioned media were prepared and collected as described fer, the positions of the RNA markers were marked on the
above. The conditioned media were precleared (1 hour, room membrane, and the nucleic acids were bound to the nylon by
temperature) using affinity purified rabbit immunoglobulin baking at 80° C for 2 hours in a vacuum oven. Membranes were
antigen-expressing retrovirus (34) were obtained from Dr. Werner
Risau, Max-Planck Institute, Bad Nauheim, Germany. These
cells also represent a stable cell line exhibiting specific endothelial cell markers. In contrast to the Py4-1 cells, they express
only polyoma middle T.antigen. All cells were maintained in
Dulbecco's modified Eagle's medium (DMEM) containing 10%
fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM sodium
pyruvate, 100 IU/ml penicillin, and 100 /xg/ml streptomycin.
BALB/C-3T3 fibroblasts (obtained from the American Type
Culture Collection, Rockville, MD) and Sl/Sld fibroblasts
(kindly provided by Dr. Alan Bernstein, Mount Sinai Hospital,
Toronto, Canada) were cultured in the same medium. MAEC
as well as brain and lung microvessel endothelial cells (also
provided by Dr. Auerbach) were cultured under similar conditions, although the microvascular cells required 20% FBS.

-ito*

MEININGER ET AL.

LABORATORY INVESTIGATION

prehybridized in a low background hybridization solution (Bio6. Dethlefsen SM, Mulliken J, Glowacki J. An ultrastructural study
of mast cell interactions in hemangiomas. Ultrastruc Pathol
tecx, Houston, TX) containing 1 M NaCl, 0.1% SDS, and IX
1986;10:175-183.
blocking reagent (Biotecx, Houston, TX) for 1 hour at room
7. Kessler DA, Langer RS, Pless NA, Folkman J. Mast cells and
temperature in a sealed bag. The prehybridization solution was
tumor angiogenesis. Int J Cane 1976;18:703-9.
removed and replaced with hybridization solution containing
8. Poole TJ, Zetter BR. Stimulation of rat peritoneal mast cell migrablocking reagent and a 32P-labeled cDNA probe (5 x 106 dpm/
tion by tumor-derived peptides. Can Res 1983;43:5857-61.
ml of hybridization solution) for murine SCF (Oncogene Sci9.
Thompson
HL, Burbelo PD, Yamada Y, Kleinman HK, Metcalfe
ence, Uniondale, NY). The hybridization reaction was carried
DD. Mast cells chemotax to laminin with enhancement after IgEout overnight at 42° C. The membrane was removed from the
mediated activation. J Immunol 1989;143:4188-92.
bag and washed at room temperature in l x SSC (20x SSC 10. Matsuura N, Zetter BR. Stimulation of mast cell chemotaxis by
contains 3 M NaCl and 0.3 M sodium citrate, pH 7) and 0.1%
interleukin 3. J Exp Med 1989;170:1421-6.
SDS three times at room temperature for 7 minutes and three 11. Meininger CJ, Yano H, Rottapel R, Bernstein A, Zsebo K, Zetter
times at 55" C for 10 minutes. After washing, the filter was
BR. The c-kit receptor ligand is a chemoattractant for mast cells.
wrapped in Saran WrapR, exposed to Kodak X-Omat AR film
Blood 1992;79:958-63.
at —70* C for 48 to 72 hours with an intensifying screen, and 12. Zsebo KM, Wypych J, McNiece IK, Lu KS, Smith KA, Karkare
SB, et al. Identification, purification and biological characterizaprocessed for autoradiography.
tion of hematopoietic stem cell factor from Buffalo rat liverReverse Transcriptase-Polymerase Chain Reaction Amplificonditioned medium. Cell 1990;63:195-201.
cation, Total RNA was isolated from cells with TriSolv™ 13. Anderson DM, Lyman SD, Baird A, Wignall JM, Eisenman J,
(Biotecx Laboratories, Houston, TX), and cDNA was generated
Rauch C, et al. Molecular cloning of mast cell growth factor, a
hematopoietin that is active in both membrane bound and soluble
using Superscript II™ (GIBCO/BRL, Gaithersburg, MD). For
forms. Cell 1990;63:235-43.
cDNA synthesis, 5 fig of total RNA in 13 p\ of diethylpyrocarbonate (DEPC)-treated water was incubated with 1 fd of 50 14. Huang E, Nocka K, Beier DR, Chu T, Buck J, Lahm H, et al. The
hematopoietic growth factor KL is encoded by the Steel locus and
ng/pl random hexamers, heated to 70* C for 10 minutes, and
is the ligand of the c-kit receptor, the gene product of the W locus.
incubated for 1 minute on ice. Added to this mixture was 2 p\
Cell 1990;63:225-33.
of buffer (200 mM Tris-HCl [pH 8.4], 500 mM KC1, 25 mM
J, Weber J, Auerbach R. A hemangioendothelioma-derived
MgCl2, 1 Mg//d bovine serum albumin), 1 pi of dNTP mixture 15. Obeso
cell line: Its use as a model for the study of endothelial cell biology.
(10 mM each of dATP, dCTP, dGTP and dTTP), 2 fd of 100
Lab Invest 1990;63:259-69.
mM DTT, and 1 pi of reverse transcriptase (200 U//d). The 16. Martin RH, Suggs SV, Langley KE, Lu HS, Ting J, Okino KH,
total mixture was incubated at room temperature for 10 minRK, et al. Primary structure and functional expression of rat and
utes, at 42° C for 50 minutes, at 70" C for 15 minutes, and then
human stem cell factor DNAs. Cell 1990;63:203-12.
placed on ice. Two units of RNase H were added, and the tube 17. Huang EJ, Nocka KH, Buck J, Besmer P. Differential expression
was incubated at 37° C for 20 minutes. The first strand cDNA
and processing of two cell associated forms of the kit-ligand: KL1 and KL-2. Mol Biol Cell 1992;3:349-62.
generated by these methods was amplified directly by adding
the following to the same tube: 8 pi of buffer (as above), 68 pi 18. Pandiella A, Bosenberg MW, Huang EJ, Besmer P, Massague J.
Cleavage of membrane-anchored growth factors involves distinct
of sterile distilled water, 2 pi of amplification primer 1 (5 pM),
protease activities regulated through common mechanisms. J Biol
2 pi of amplification primer 2 (5 piA), and 2 to 5 units of Taq
Chem 1992;267:24028-33.
polymerase (GIBCO/BRL). The primers used were: 5'-TGGHS, Clogston CL, Wypych J, Fausset PR, Lauren S, Mendiaz
TGGCATCTGACACTAGTGACTGT-3' and 5'-TGTCAAT- 19. Lu
EA, et al. Amino acid sequence and post-translational modification
TGTAGGCCCGAGTCTTCA-3'. The reaction mixture was
of stem cell factor isolated from buffalo rat liver cell-conditioned
heated to 94* C for 5 minutes to denature the RNA/cDNA
medium. J Biol Chem 1991;266:8102-7.
hybrid, and polymerase chain reaction was carried out for 30 20. Arakawa T, Ypljantis DA, Lary JW, Narhi LO, Lu HS, et al.
cycles. The amplified DNA fragments were separated on an 8%
Glycosylated and unglycosylated recombinant-derived human stem
polyacrylamide gel under nondenaturing conditions and were
cell factors are dimeric and have extensive secondary structure. J
visualized by staining with silver stain (BioRad, Richmond, CA).
Biol Chem 1991;266:18942-8.
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